Characterization of B Lymphocyte Deficiency in Pediatric Sickle Cell Disease
Characterization of B Lymphocyte Deficiency in Pediatric Sickle Cell Disease
批准号:
10641800
负责人:
Venee N Tubman
金额:
$16.32万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-06-20 至 2025-05-31
关键词:
5 year oldANXA5 geneAbnormal CellAcuteAfricaAfrica South of the SaharaAgeApoptosisB cell differentiationB-Cell DevelopmentB-Lymphocyte SubsetsB-LymphocytesBCL2 geneBacteremiaCASP3 geneCessation of lifeChestChildChildhoodClinicalCoculture TechniquesCustomCytokine SignalingDevelopmentDiseaseEnrollmentEnvironmentEnzyme-Linked Immunosorbent AssayExposure toFundingGoalsHistopathologyHuman Herpesvirus 4ImmuneImmune responseImmune systemImpairmentIn VitroInfectionInflammatoryInnate Immune ResponseIntrinsic factorInvestigationKineticsLifeLymphocyte CountMalariaMarginal Zone B-LymphocyteMeasuresMemory B-LymphocyteMentorshipModelingMonitorMorbidity - disease rateNatural ImmunityOsteomyelitisPatientsPlasma CellsPlasmodiumPopulationProliferatingResearchResearch PersonnelRisk AssessmentRisk ReductionRoleSamplingSerumSickle Cell AnemiaSpleenSystemT-LymphocyteTanzaniaTexasTherapeuticTissue BanksTissuesTrainingViralVirusWorkbiomarker developmentclinical phenotypecohortcytokinedriver mutationexperiencehumoral immunity deficiencyimmune functioninfancyinfection riskinflammatory milieuinsightmortalitynew therapeutic targetpathogenpatient stratificationperipheral bloodprogramsrisk stratificationsample collectiontherapeutic biomarkertherapeutic targettool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
PROJECT SUMMARY
Infections are frequent complications in sickle cell disease (SCD), occurring in up to 45% of patients. In Africa,
where up to 90% of children with SCD die by age 5 years, many of these deaths are attributed to infection. In
SCD, the spleen is damaged in infancy and results in marginal zone B cell deficiency. The clinical implications
of B cell deficiency in SCD are not fully understood and requires investigating both disease-intrinsic and -
extrinsic modifiers of B cell subsets. In this investigation, I will quantify B cell subsets in children with and
without SCD in Texas and in Tanzania, investigate mechanisms of B cell deficiency, and compare them to
important clinical endpoints.
Aim 1: Characterize mechanisms of MZB deficiency in SCD. Hypotheses: There is a difference in the
development, survival, and function of B cells from SCD and non-SCD subjects due to B-cell intrinsic factors.
Differences in B cell populations may be due to differences in kinetics of differentiation and proliferation and/or
survival. To examine differentiation and proliferation, I will measure the efficiency of differentiation of
transitional B cells from SCD and non-SCD donors into MZBs, and MZBs into plasma cells using an in vitro B
cell co-culture system. To examine survival, I will measure the rate of apoptosis and expression of markers of
apoptosis (e.g. annexin V, caspase 3/9, BCL2) in native and culture-derived MZBs in culture.
Aim 2: Determine the effect of the microenvironment of the spleen in SCD on B cells. Hypothesis:
Extrinsic factors such as the inflammatory environment in SCD impair B cell development, survival, and
function. To examine the effect of the microenvironment on B cells in culture, I will culture non-SCD B cells in
media supplemented with SCD serum or spleen extract. To investigate which components of the extract impact
B cells, I will develop a cytokine profile for the extract and serum using multiplex ELISA.
Aim 3: Determine whether low MZB is associated with infectious and inflammatory complications of
SCD. Hypothesis: Life-threatening infections in SCD are more common among children with severe MZB
deficiency. To determine whether B-cell tropic viruses have a confounding effect on MZB number, I will
measure immune response to EBV and malaria using a custom multiplex ELISA panel. To determine whether
infectious complications are associated with more severe MZB deficiency in SCD, I will compare MZB among
children with and without complications such as acute chest, osteomyelitis, or bacteremia.
Despite a shared driver mutation, the clinical phenotype in SCD is highly variable. Together, the studies in this
proposal will overcome critical barriers to risk-stratifying patients for infectious and inflammatory complications
of SCD. Increased insights into how SCD catalyzes B cell deficiency may help identify novel therapeutic
targets or biomarkers to mitigate the impact of infections on SCD. My central hypothesis is that B cell
abnormalities contribute to morbidity and mortality in children with SCD.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1002/pbc.29695
发表时间:
2022-06
期刊:
Pediatric blood & cancer
影响因子:
3.2
作者:
[]
通讯作者:
DOI:
10.1021/acs.analchem.0c04191
发表时间:
2021-03-23
期刊:
Analytical chemistry
影响因子:
7.4
作者:
[Natoli ME, Chang MM, Kundrod KA, Coole JB, Airewele GE, Tubman VN, Richards-Kortum RR]
通讯作者:
Richards-Kortum RR
Unique Hemoglobinopathy Pattern Following Treatment with Voxelotor.
Voxelotor 治疗后独特的血红蛋白病模式。
DOI:
--
发表时间:
2023
期刊:
Annals of clinical and laboratory science
影响因子:
0.8
作者:
[Poventud-Fuentes,Izmarie, Portillo,TaniaPlatero, Olayinka,Lily, Marcogliese,AndreaN, Tubman,VenéeN, Devaraj,Sridevi]
通讯作者:
Devaraj,Sridevi
Determinants of retention in care of newborns diagnosed with sickle cell disease in Liberia: Results from a mixed-methods study of caregivers.
利比里亚诊断出患有镰状细胞病的新生儿保留的决定因素:由治疗者进行混合方法的结果。
DOI:
10.1371/journal.pgph.0001705
发表时间:
2023
期刊:
PLOS global public health
影响因子:
--
作者:
[]
通讯作者:
DOI:
10.1097/moh.0000000000000738
发表时间:
2022-11-01
期刊:
CURRENT OPINION IN HEMATOLOGY
影响因子:
3.2
作者:
[John, Tami D., Namazzi, Ruth, Chirande, Lulu, Tubman, Venee N.]
通讯作者:
Tubman, Venee N.
共 8 条
Characterization of B Lymphocyte Deficiency in Pediatric Sickle Cell Disease
-
批准号:10465088
-
项目类别:
-
资助金额:$16.32万
-
财政年份:2020
-
负责人:Venee N Tubman
-
依托单位:
Characterization of B Lymphocyte Deficiency in Pediatric Sickle Cell Disease
-
批准号:10199779
-
项目类别:
-
资助金额:$16.32万
-
财政年份:2020
-
负责人:Venee N Tubman
-
依托单位:
Characterization of B Lymphocyte Deficiency in Pediatric Sickle Cell Disease
-
批准号:9977549
-
项目类别:
-
资助金额:$16.32万
-
财政年份:2020
-
负责人:Venee N Tubman
-
依托单位: